Summary

Purdue Pharma filed a revised bankruptcy plan to finalize a $7.4 billion opioid settlement after the U.S. Supreme Court blocked a previous deal.

The plan increases the Sackler family’s contribution to up to $7 billion but allows creditors to opt out and sue the Sacklers directly.

Purdue will pay $900 million and become a public benefit company.

The settlement allocates $850 million to individuals harmed by opioids, with most funds directed to states and communities for addiction treatment and prevention programs.